Levoxin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levoxin

Property Description
Active ingredient Levofloxacin (often as the hemihydrate)
Forms Tablet, Oral Solution, Intravenous (IV) Solution, Ophthalmic Solution
Pharmacological class Fluoroquinolone Antibiotic (Quinolone class)
Common use Resolution of bacterial infections
Origin Synthetic (refined S-enantiomer)

What Type of Medicine is Levoxin?

Levoxin is a prescription-only medicinal product containing the active substance Levofloxacin, which is a broad-spectrum antibacterial agent belonging to the modern Fluoroquinolone class of antibiotics. This entire pharmacological class is synthetic and is clinically recognized for its targeted efficacy against a wide range of bacterial pathogens. Levofloxacin is specifically the active S-(-)-enantiomer derived from Ofloxacin, which is a key differentiating factor that optimizes its pharmacological profile. Levofloxacin works to eliminate bacteria by interfering with their DNA. This confirms that the medicine’s core purpose is to actively eliminate the pathogens causing infection.

Composition and Available Forms

Levoxin is a single-active-ingredient product supplied in forms designed for systemic and localized administration. The core component is pure Levofloxacin, typically in its stable hemihydrate salt form. Common dosage form(s) include oral tablets and liquid oral solution, as well as preparations for intravenous (IV) solution and ophthalmic solution. This diverse availability allows the drug to be administered orally, parenterally, or topically, offering flexibility in treating various infection sites.

General Therapeutic Purpose

The overall purpose of Levoxin is to rapidly resolve infections through its bactericidal activity, meaning it directly kills the susceptible bacteria. Its mechanism involves disrupting the life-sustaining processes of the pathogen by interfering with vital enzymes—specifically DNA Gyrase and Topoisomerase IV. The Fluoroquinolone class generally demonstrates high bioavailability across various routes of administration, supporting its efficacy for treating systemic infections. This characteristic ensures the medicine reaches the required concentration in the body to effectively clear both localized and systemic bacterial infections in adult patients.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Levoxin?

Adverse Reaction Scope

Levoxin's safety profile, based on regulatory documentation, involves adverse reactions categorized by frequency and the physiological system affected. Common reactions (occurring in ge 1/100 patients) typically involve gastrointestinal and central nervous system effects, such as nausea, diarrhea, headache, and insomnia. Reactions classified as Rare or Not Known (incidence cannot be precisely estimated) include the most clinically significant concerns.


Serious and Disabling Adverse Reactions

Government health authorities specifically highlight a set of serious, disabling, and potentially irreversible adverse reactions affecting multiple body systems. These include tendinitis and tendon rupture (often involving the Achilles tendon), peripheral neuropathy (nerve damage), and severe central nervous system effects such as convulsions and psychotic reactions. Serious effects on other organ systems include Aortic Aneurysm and Dissection, Severe Hepatotoxicity (liver injury), hypoglycemia that may lead to coma, and QT interval prolongation, which carries a risk of life-threatening heart rhythm disturbances.


Population-Specific Safety Considerations and Patterns

The official labeling notes that the risk of tendon injury is increased in older patients (typically over 60 years of age), in patients with renal impairment, and in those who have received a solid organ transplant. The risk of severe hepatotoxicity is also heightened in older patients. Furthermore, some serious reactions, including anaphylactic reactions and CNS effects, may occur after the first dose, while tendon rupture has been documented to occur up to several months after treatment completion.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based strictly on the officially documented descriptions and actions required by regulatory authorities for Levofloxacin overdosage.

Overdose manifestations primarily affect the Central Nervous System (CNS) and the Cardiovascular system. Documented presentations include convulsions, tremors, ataxia (loss of coordination), and ptosis (drooping eyelids). Severe outcomes associated with high systemic levels include QT interval prolongation, carrying the risk of a serious ventricular arrhythmia known as Torsade de Pointes.

Immediate medical attention is required upon the onset of any severe clinical signs or suspected overdosage. The medication must be discontinued immediately if symptoms such as convulsions or signs of severe toxicity appear.

Management in an overdose situation is focused on supportive care, as no specific antidote is known. Officially described management procedures include emptying the stomach for acute oral overdosage and maintaining appropriate hydration. Regulatory documents also specify the need for close patient observation, continuous ECG monitoring for cardiac risk, and blood glucose monitoring.

Patients with impaired renal function or those predisposed to seizures are noted in regulatory information to be at increased risk of toxicity from overexposure.

Therapeutic Uses of Levoxin

Levoxin is a prescription medicine generally applied in contexts involving symptoms related to systemic imbalance and symptoms that create noticeable physiological strain, to address the condition. This agent is relevant in conditions associated with acute or disruptive episodes, including severe lung infections like pneumonia, complicated urinary tract infections (UTIs) and pyelonephritis, chronic bacterial prostatitis, complicated skin and soft tissue infections, and specific high-risk scenarios such as post-exposure prophylaxis for inhalational anthrax.


Addressing Acute Symptom Clusters

The primary therapeutic benefit lies in supporting the patient during difficult episodes. Treatment in this domain contributes to easing the overall symptom load associated with infection. This medication is used when groups of symptoms appear suddenly or fluctuate, and supportive symptom management is appropriate. This medication is commonly used when symptoms intensify and supportive relief is needed, particularly for acute flares of chronic bronchitis. Its use may assist with managing intense symptoms like painful urination (dysuria) and flank discomfort, supporting patients during difficult episodes by easing distress and maintaining functional stability. The medicine may be part of symptomatic management in scenarios involving high-risk public health protocols.

Quick Fact: Supportive Management for Systemic Discomfort

Levoxin helps manage accompanying symptoms related to systemic imbalance, like fever and chills, and is relevant across acute therapeutic contexts.

Eligibility and Restrictions for Use

Eligibility Scope

Levoxin (Levofloxacin) is an antibiotic reserved primarily for adult patients and is subject to strict eligibility rules defined by regulatory authorities.

Population Group Eligibility Status (Systemic Use)
Adults (ge 18 years) Eligible for approved systemic infections.
Children/Adolescents (< 18 years) Contraindicated for routine use due to the risk of joint cartilage damage; use is reserved only for specific life-threatening infections like Anthrax or Plague, as determined by a risk-benefit assessment.
Pregnant Women Contraindicated or Not Recommended due to potential risks to the fetus and the lack of human safety data.
Breastfeeding Women Contraindicated or Not Recommended as Levofloxacin is excreted into human milk.

Absolute Contraindications

Levoxin must not be used in patients with:

  • A known history of hypersensitivity or allergy to levofloxacin or any other fluoroquinolone drug.
  • A history of tendon disorders (e.g., tendinitis, rupture) related to previous use of any quinolone or fluoroquinolone antibiotic.
  • Epilepsy (listed as a contraindication in some regulatory documents).

Restricted or Conditional Use

Use requires special caution and may necessitate mandatory dose adjustments in the following populations:

  • Renal Impairment: Patients with reduced kidney function require a mandatory dosage adjustment to prevent drug accumulation.
  • Older Adults (ge 60 years): Eligible but are at a higher risk of tendon disorders and QTc prolongation.
  • Myasthenia Gravis: Use is strongly avoided, as Levofloxacin may exacerbate muscle weakness.
  • Cardiac Risk Factors: Patients with uncorrected hypokalemia or other risk factors for QTc interval prolongation require careful monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Levofloxacin (Levoxin) interaction patterns are formally documented by regulatory authorities, requiring specific administration rules and restrictions for co-administration with other substances.

Interaction Classifications

Classification Regulatory Information Summary
Contraindicated Combination Co-administration with medicinal products known to prolong the QT interval is restricted due to an additive pharmacodynamic risk of cardiac repolarization effects.
Timing-Based Restriction Oral Levofloxacin must not be taken within 2 hours of multivalent cation-containing products (e.g., antacids, iron, zinc, Sucralfate, or buffered Didanosine) to prevent chelation and subsequent reduction in drug absorption.

Pharmacokinetic and Pharmacodynamic Effects

Co-administration with systemic Corticosteroids carries an additive risk that increases the likelihood of tendinitis and tendon rupture, a risk that is further heightened in elderly patients. The combination with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may lower the cerebral seizure threshold. The effect of Vitamin K Antagonists (e.g., Warfarin) may be enhanced, necessitating monitoring of coagulation tests. Furthermore, agents like Probenecid and Cimetidine interact by inhibiting renal tubular secretion, which reduces Levofloxacin's overall renal clearance. Co-administration with Antidiabetic Agents is associated with documented disturbances in blood glucose.

Mechanism of Action

Levofloxacin is an agent that produces a bactericidal effect by interfering with the genetic material of bacterial cells. Its mechanism relies on disrupting essential life processes within the pathogen, leading to bacterial cell death.

Targeting Bacterial DNA Processing Enzymes

This domain covers the drug’s primary molecular targets: the bacterial enzymes DNA Gyrase and Topoisomerase IV. Levofloxacin acts as a catalytic inhibitor by stabilizing the complex formed between the enzyme and the bacterial DNA after the DNA strand has been cleaved. This trapping prevents the crucial final step of the enzymatic process—the re-ligation of the broken DNA. This focused action is the basis for the drug's bactericidal activity.

Cascade of Lethal Genomic Damage

The physical blockade of the re-ligation step initiates a cellular crisis: the cumulative accumulation of irreversible double-strand DNA breaks throughout the bacterial chromosome. This massive damage immediately halts DNA replication, transcription, and chromosome segregation, which are vital for growth and division. The physiological consequence of this genomic failure is the irreversible destruction of the bacterial organism (bactericidal effect).

️ Constraints on Mechanistic Effectiveness

The effectiveness of this mechanism can be physiologically constrained by bacterial defense systems. Resistance typically involves genetic changes (boldsymbolg y r A and boldsymbolp a r C mutations) that reduce the enzyme targets' affinity for the drug, or the activation of efflux pumps that actively expel the drug from the bacterial cell. These constraints limit the drug's ability to reach the necessary intracellular concentration to initiate the DNA damage cascade.

Dosage and Administration Information

Levoxin (Levofloxacin) is administered via the oral route (tablets or solution), by slow intravenous (IV) infusion, or as an ophthalmic solution. The prescribed dosage, typically ranging from 250 mg to 750 mg once daily, depends on the type of infection being treated.

Administration and Timing Requirements

Administration Type Instruction
Oral Tablets May be taken with or without food.
Oral Solution Must be taken one hour before or two hours after meals.
Cation-Containing Agents Oral forms must be taken at least two hours before or two hours after products containing multivalent cations (e.g., antacids with magnesium/aluminum, iron, or zinc).
Intravenous (IV) Infusion Must be administered by slow infusion over 60 minutes for a 500 mg dose or 90 minutes for a 750 mg dose; rapid or bolus injection is forbidden.

Population-Specific Dosing Rules

  • Renal Impairment: Mandatory dose reduction or extension of the dosing interval (e.g., every 48 hours) is required for adult patients with impaired renal function (Creatinine Clearance < 50 mL/min).
  • Pediatric Use: Levofloxacin is generally contraindicated in children and growing adolescents. Usage in pediatric patients (6 months and older) is recognized for specific high-risk indications (e.g., Inhalational Anthrax Post-Exposure), using a weight-based dose.

Administration should be continued for the duration prescribed, which may range from 3 days (e.g., uncomplicated urinary tract infection) up to 60 days (e.g., Anthrax Post-Exposure Prophylaxis).

Recent Clinical Evidence

Levoxin: Recent Clinical Evidence

Levoxin (levofloxacin), a broad-spectrum fluoroquinolone antibiotic, has been studied in numerous clinical trials for its use against various bacterial infections. Research focuses on its potential role in treating conditions such as Community-Acquired Pneumonia (CAP), complicated and uncomplicated urinary tract infections (UTI), acute bacterial sinusitis, and chronic bacterial prostatitis.


Efficacy Data from Clinical Trials

Phase 3 and post-marketing observational studies suggest that, for adults with CAP, Levoxin 500 mg administered once daily was associated with a high rate of clinical success in evaluable patients. A common finding across these trials is that Levoxin regimens, including a high-dose, short-course (e.g., 750 mg for five days), have shown comparable clinical success and microbiological eradication rates when compared to conventional regimens (e.g., 500 mg for 10-14 days) in the treatment of acute bacterial infections like CAP and complicated UTI/acute pyelonephritis. This suggests that a shorter duration of treatment may be an option for certain patients, a conclusion supported by pooled analysis of relevant randomized investigations.

Safety and Tolerability Profile

The safety profile observed in clinical research generally aligns with the established risks for the fluoroquinolone class. The most frequently reported adverse events in clinical trials often include gastrointestinal issues (such as nausea and diarrhea) and central nervous system effects (like headache and dizziness).

However, a crucial finding highlighted in regulatory communications and post-marketing surveillance is the association of fluoroquinolones with disabling and potentially irreversible serious adverse reactions. These reactions may involve tendon disorders (including tendinitis and tendon rupture), peripheral neuropathy, and central nervous system effects. Clinical evidence indicates that the risk of such events is higher in older patients and those receiving concomitant corticosteroid therapy. Immediate discontinuation is advised for patients who observe symptoms related to these serious reactions.

Key Studies & References Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects - GOV.UK (MHRA Safety Update)

Frequently Asked Questions (FAQ)

Common questions about Levoxin (FAQ)


Q: Does Levoxin start working right away, or does it take a few days?

Official information indicates that Levoxin reaches its highest concentration in the body within one to two hours after being administered. However, the time it takes for infection symptoms to visibly improve often varies. Clinical trial data suggests that the expected rate of recovery depends on the specific type and severity of the infection being addressed.


Q: Is it true that Levoxin can cause joint pain or tendon issues?

Yes, official regulatory warnings describe an association between this class of medication and disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture. Symptoms of these serious events may include new pain, swelling, or inflammation in a tendon, such as those in the shoulder, hand, or heel. The regulatory label advises seeking prompt medical attention if these symptoms are experienced.


Q: Why do some official sources mention a risk of nerve damage with this drug class?

Regulatory documents explicitly highlight the risk of peripheral neuropathy, which is described as nerve damage involving pain, burning, tingling, numbness, or weakness. This can begin quickly after starting the medicine. Official sources indicate that this nerve damage has been reported to be potentially irreversible.


Q: Are there any specific mental health side effects listed for Levoxin?

The official label lists various central nervous system (CNS) effects that have been reported with Levoxin. Specific reports include anxiety, insomnia, depression, hallucinations, and confusion. The official product information advises seeking prompt medical attention if these effects occur.


Q: Can Levoxin cause sun sensitivity or skin reactions?

Regulatory data indicates that Levoxin, like other drugs in its class, can cause photosensitivity, which is an increased sensitivity to the sun. Because of this, official sources often recommend minimizing sun exposure. Other skin reactions, including rash, are also reported.


Q: Does Levoxin interact with common supplements like multivitamins?

The official label advises specific administration timing regarding oral forms of Levoxin and products containing multivalent cations. Cations like iron, zinc, or magnesium are often found in multivitamins and mineral supplements. To prevent the reduction of drug absorption, these products must not be taken within two hours of Levoxin.


Q: Do I need to take Levoxin with food or on an empty stomach?

The required timing depends on the specific formulation being used. Levoxin oral tablets may generally be taken with or without food. However, if using the oral solution, official guidance states that it must be taken either one hour before or two hours after meals.


Q: What happens if I accidentally take too much Levoxin?

Official documentation describes that symptoms of a suspected overdose may include confusion, dizziness, impaired consciousness, seizures, and prolonged QT interval (a change in heart rhythm). The regulatory label does not provide personal instructions for managing an overdose. In cases of suspected overdose, official guidance is to seek immediate medical assistance.


Q: What is the difference between Levoxin and antibiotics ending in '-mycin'?

Levoxin belongs to the fluoroquinolone class and works by inhibiting key bacterial enzymes that manage DNA. In contrast, antibiotics ending in '-mycin' typically belong to different classes, such as macrolides or aminoglycosides, which work through a different mechanism, often by disrupting the bacteria’s ability to create proteins.


Q: Do studies suggest Levoxin is effective for chronic conditions?

Levoxin is approved for treating a range of bacterial infections, and some conditions, such as chronic bacterial prostatitis, are chronic in nature. Clinical trials have been conducted to examine the effectiveness of Levoxin for these specific, approved long-term indications.


Q: Is Levoxin known to cause changes in sleep patterns?

Official drug information lists 'trouble sleeping' (insomnia) as one of the common side effects that can occur. These sleep disturbances are related to the potential central nervous system effects of the medication.


Q: Is Levoxin considered a high-risk medication?

Due to the potential for disabling and potentially irreversible serious adverse reactions, the FDA advises that for certain uncomplicated infections (like uncomplicated UTI), Levoxin should be reserved for use in patients who have no alternative treatment options. This is a measure to balance the drug’s benefits against its risks.


Q: Can Levoxin affect blood sugar levels?

Yes, regulatory warnings state that Levoxin is associated with documented disturbances in blood glucose levels. These disturbances can include both high blood sugar (hyperglycemia) and serious low blood sugar (hypoglycemia), which is a risk for all patients, not just those with pre-existing diabetes.


Q: If I feel better, is it okay to stop using Levoxin earlier than planned?

Regulatory guidance emphasizes that Levoxin should be used for the full treatment time prescribed by a health professional, even if symptoms begin to improve quickly. Stopping the medicine too soon may not fully clear the infection, and there is a documented risk that stopping early may contribute to the development of drug-resistant bacteria.


Q: What are the typical expected results from using Levoxin?

The intended result of using Levoxin is the control of the specific bacterial infection for which it was prescribed. Clinical trial data supports high rates of clinical success and the eradication of susceptible bacteria in patients treated for the approved indications.


Q: What is the role of Levoxin in treating infections in different parts of the body?

Levoxin is approved for treating bacterial infections in various systems of the body, including the respiratory tract, urinary tract, skin and soft tissue, and prostate. Official data confirms that the medicine achieves effective concentrations in many tissues and body fluids, which allows it to target bacteria in these diverse locations.


Q: Is the long-term use of Levoxin being studied?

Treatment courses for most infections are generally short, ranging from 5 to 14 days. However, the longest duration approved by the FDA is up to 60 days for specific, rare indications. Official product information indicates that the safety of therapy durations exceeding 28 days has not been established for the most common uses.


Q: Are there generic versions of Levoxin available?

Yes, the active substance Levofloxacin is available as a generic medicine. Generic versions contain the same active ingredient and meet the same regulatory quality and efficacy standards as the branded form.


Q: Why are there different dosages of Levoxin, and what do they mean?

Official regulatory documents define different dosages (e.g., 250 mg, 500 mg, or 750 mg) because the required amount of medicine is based on the type of infection being treated. The dosage is determined by factors like the location of the infection and the anticipated susceptibility of the bacteria.


Q: Are there different forms of Levoxin (e.g., tablet, liquid, injection)?

Yes, Levoxin is available in multiple forms, as listed in official drug documents. These include oral tablets, an oral solution for swallowing, a solution for slow intravenous (IV) infusion, and an ophthalmic (eye drop) solution for treating certain eye infections.


Q: What kind of research has been done on Levoxin's safety profile?

Safety research includes data collected from Phase 3 clinical trials, which test the drug in large patient groups prior to approval. Additionally, ongoing post-marketing surveillance reports document serious adverse events that occur during the routine use of the medication.


Q: Is there a maximum amount of time a person should use Levoxin?

While most courses are short, the longest duration approved by the FDA is up to 60 days for specific high-risk exposures like inhalational anthrax post-exposure prophylaxis. The specific duration prescribed will be based on the infection being treated.


Q: Why is Levoxin sometimes saved as a 'last resort' option?

The FDA requires that for certain uncomplicated infections, Levoxin should be reserved for use in patients who have no alternative treatment options. This is specifically due to the risk of serious adverse reactions, and the reserve-use statement is intended to mitigate that risk when other suitable options are available.


Q: Can Levoxin cause issues with the heart rhythm?

Yes, the official label contains a warning regarding the potential for Levoxin to cause prolongation of the QT interval, which is an electrical change in the heart. This change can be associated with serious, sometimes fatal, irregular heart rhythms.


Q: What is the most serious, yet rare, side effect associated with Levoxin?

Regulatory documents highlight the association with disabling and potentially irreversible serious adverse reactions, such as tendon rupture. Very rare but serious events like severe allergic reactions (anaphylaxis) are also reported in official safety profiles.


Q: If I am taking Levoxin, can I still drive or operate machinery?

Official guidance advises caution due to the potential for central nervous system effects, such as dizziness, lightheadedness, and vision changes. People are advised not to drive or operate machinery until they are aware of how the medicine specifically affects them.


Q: Do people often report stomach upset or nausea with Levoxin?

Yes, nausea, vomiting, and diarrhea are listed in regulatory documents as some of the most frequently reported adverse effects observed in clinical trials. These are common gastrointestinal issues associated with the drug.


Q: Do official documents address the development of drug resistance with Levoxin?

Yes, official documents warn that taking the drug when it is not needed or stopping treatment too soon can contribute to the development of drug-resistant bacteria. They also note that resistance mechanisms within the bacteria can limit the drug's effectiveness.


Q: Is there any concern about Levoxin affecting liver function?

Official information includes warnings regarding the potential for severe, sometimes fatal, hepatotoxicity (liver damage). Regulatory advice states that discontinuation of the drug is necessary if signs and symptoms of hepatitis (like jaundice) occur.


Q: Is it true that Levoxin can cause confusion or strange dreams?

Yes, the official adverse reactions list includes confusion and 'bad dreams' (nightmares) as central nervous system effects that have been reported during use. These effects should be promptly reported to a healthcare provider.


Q: Does the time of day matter when using Levoxin?

Regulatory guidance requires specific timing relative to meals (for the oral solution) and the use of multivalent cations (like antacids). However, the official label does not specify a general requirement to take the medicine in the morning versus the evening.


Q: What should I do if a specific side effect is getting worse?

The official Patient Medication Guide emphasizes that users are advised to contact their healthcare provider right away if any side effect becomes severe, persistent, or is getting worse. For serious effects like tendon pain or neuropathy, immediate discontinuation is specifically advised.


Q: Are there specific patient groups that need extra caution with Levoxin?

Yes, official warnings indicate that the risks of serious adverse reactions, such as tendon issues, are higher in several patient groups. These include older adults, patients receiving concomitant corticosteroid therapy, and those with heart, kidney, or lung transplants.


Q: Can Levoxin cause allergic reactions, and what are the signs?

Yes, Levoxin is contraindicated in patients hypersensitive to it or other quinolone antibiotics. Serious allergic reactions, which can be life-threatening, may occur. Official documents describe signs of a serious allergic reaction, which may include rash, hives, swelling of the face or throat, and difficulty breathing.


Q: How does Levoxin differ from penicillin-based drugs?

Levoxin belongs to the fluoroquinolone class and kills bacteria by disrupting their DNA replication processes. Penicillin-based drugs belong to the beta-lactam class and work through a different method, primarily by interfering with the building of the bacterial cell wall.

How should Levoxin be stored and disposed of?

Storage and Disposal Requirements for Levoxin (Levofloxacin)

The official labeling mandates specific conditions for storing Levoxin to maintain product integrity and ensure safety.

Storage Conditions

Levoxin must be stored at room temperature, generally between 20^circC to 25^circC, and should not exceed 30^circC. The medication must be kept protected from light and away from excess heat and moisture. The intravenous solution is explicitly labeled Do Not Freeze. The medicine must remain in its original, tightly closed container and be stored out of the sight and reach of children.

Disposal

Unused or expired product must be properly disposed of according to local, regional, and national regulations. Official guidelines state that the medicine should not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levoxin found in:

A-Z Index: